Hutchison China Meditech Limited Block Admission (8055L)
April 23 2018 - 7:05AM
UK Regulatory
TIDMHCM
RNS Number : 8055L
Hutchison China Meditech Limited
23 April 2018
Block Admission
London: Monday, April 23, 2018: Hutchison China MediTech Limited
("Chi-Med") (AIM/Nasdaq: HCM) today announces that an application
has been made to the London Stock Exchange plc for a block
admission of 1,425,597 ordinary shares, par value of US$1.00 each
("Ordinary Shares") to be admitted to trading on AIM. It is
expected that such admission will become effective on April 27,
2018.
These Ordinary Shares will be issued from time to time pursuant
to the exercise of share options under the Share Option Scheme
conditionally adopted by Chi-Med in 2015 (the "2015 HCML Share
Option Scheme"). When issued, these Ordinary Shares will be
credited as fully paid and will rank pari passu with the existing
Ordinary Shares in issue.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
Forward Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve risks and uncertainties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
Chi-Med's filings with the U.S. Securities and Exchange Commission
and on AIM. Chi-Med undertakes no obligation to update or revise
the information contained in this announcement, whether as a result
of new information, future events or circumstances or
otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President, Corporate
Finance & Development +852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedewerogerson.com
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSLXLFLVZFBBBB
(END) Dow Jones Newswires
April 23, 2018 08:05 ET (12:05 GMT)
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From May 2023 to May 2024